Medscape is available in 5 Language Editions – Choose your Edition here.


Delirium Tremens (DTs) Medication

  • Author: Michael James Burns, MD, FACEP, FACP; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM  more...
Updated: Apr 14, 2016

Medication Summary

Although thiamine has no effect on the symptoms or signs of alcohol withdrawal or on the incidence of seizures or delirium tremens (DTs), thiamine (100 mg PO/IV/IM qd for 3 d) is useful in preventing Wernicke encephalopathy and Wernicke-Korsakoff syndrome. Multivitamins (PO/IV qd) and folate (1 mg PO/IV qd) are frequently administered to these patients, but no evidence exists that vitamins, other than thiamine, have any benefit in the acute setting.

Many varying pharmacotherapeutic management recommendations exist for alcohol withdrawal and DTs. Even many authoritative textbooks and journal articles have made recommendations for use of pharmacotherapeutic agents that have never been tested in clinical trials for this condition.

Benzodiazepines are considered the drugs of choice for the management of all stages of alcohol withdrawal syndrome, including DTs. They act on the benzodiazepine-GABA-chloride receptor complex, having a similar GABA-potentiating effect as alcohol. Prospective, randomized clinical trials have demonstrated the effectiveness of benzodiazepines in treating the symptoms and signs of alcohol withdrawal and have also shown a protective benefit against seizures.[18] Although they are thought by many to have a high margin of safety, the heterogeneity of the trials in interventions and in assessment of outcomes prevent definitive conclusions about safety and harms.

The longer-acting benzodiazepines, such as chlordiazepoxide and diazepam, appear to be more effective at preventing the serious complications of seizures and DTs than are shorter-acting benzodiazepines such as alprazolam and oxazepam. Most experts recommend that intermittent IV bolus dosing of diazepam or lorazepam is the treatment of choice for drug therapy of DTs. In patients refractory to benzodiazepine therapy alone, barbiturates or propofol, and occasionally other drugs, may be added.[19]

Phenobarbital, a long-acting barbiturate with a half-life of 80-120 hours and a duration of sedation of 4-10 hours, has been used successfully in the treatment of alcohol withdrawal and DTs. It has well-documented anticonvulsant activity, is inexpensive, and can be administered by the oral, intramuscular, or IV route. Although its mechanism of action is mediated by GABA at the GABA-A receptor, its mechanism of action is different from the benzodiazepines as well as the short-acting barbiturates. While benzodiazepines increase the frequency of chloride channel opening caused by GABA-A receptor activation requiring the presence of presynaptic GABA, phenobarbital enhances GABA-A chloride currents by increasing the duration of chloride channel opening. Therefore, phenobarbital and benzodiazepines may have synergistic clinical effects, supporting the use of phenobarbital as an adjunct to benzodiazepines.

However, compared with benzodiazepines, even at high doses, phenobarbital has a greater risk of respiratory depression and hypotension and has a lower overall safety profile. It is generally recommended to be reserved for use as an alternative agent when benzodiazepines cannot be used or have not been effective.[20] Some authorities have recommended phenobarbital as a first-line agent to be given as an initial single large dose up to 10 mg/kg or preferably as repeated small doses (65, 130, or 260 mg IV per dose) for loading until the patient is calm, to be followed by use of benzodiazepines on an as-needed, symptom-triggered basis.

An appropriate use for phenobarbital might be a situation in which agitation has not been controlled well with high doses of benzodiazepines. Then, one could administer a small dose of phenobarbital and repeat every 30 minutes until sedation occurs.

A single dose of intravenous phenobarbital given in the emergency department may decrease the subsequent ICU admission rate and decrease the total dose of benzodiazepine and decrease the use of continuous lorazepam infusions required during the hospital course, without any increased adverse effects.[21]

Some patients are discharged from the emergency department (ED) or hospital to a setting where medical supervision of detoxification and withdrawal is not available. If this is the case, treatment with a sedative agent that has a long duration of action, such as phenobarbital or a long-acting benzodiazepine (eg, diazepam, chlordiazepoxide), in the ED or hospital may be preferable and safer. Because the effect of these drugs may persist for several days after the last dose, this avoids the less desirable option of prescribing sedative agents for patients to take at home in an unsupervised manner. A patient who is discharged home to a nonmedically supervised environment with a prescription for a benzodiazepine or other sedative-hypnotic agent may misuse the drug, will often resume alcohol at the same time, and may resell the drugs or share them with other persons.

For patients with refractory DTs, propofol has been described in case studies as effective in managing patients who are intubated.[19] It has effects on NMDA and GABA receptors. No clinical trial has demonstrated any superiority over benzodiazepines.

Use of intravenous dexmedetomidine, an alpha-2 receptor antagonist with sedative and sympatholytic properties, is also an option for refractory DTs. It alleviates agitation, causes less respiratory depression, and may be given without mechanical ventilation, unlike propofol. It has been used with benzodiazepines as adjunctive therapy and may reduce total benzodiazepine dosage, but with the risk of producing bradycardia and hypotension.[22]  A 2015 review of English-language studies of dexmedetomidine for alcohol withdrawal, none of which was of high quality, found that dexmedetomidine appears to reduce benzodiazepine requirements and decreases sympathomimetic responses, but without convincing evidence that it improves clinical endpoints, including need for mechanical ventilation or length of stay.[23]

Clonidine and beta-blockers have been used to treat the hyperadrenergic state of alcohol withdrawal. Although these agents may correct some of the autonomic manifestations of withdrawal, they have not been demonstrated to have any effect on seizures or DTs, and they should be used only in conjunction with benzodiazepines in the treatment of patients with alcohol withdrawal. The recommended dose for clonidine is 0.2 mg orally bid, but this dose should be individualized. Beta-blockers may obscure the vital sign abnormalities that occur early in alcohol withdrawal and prevent early recognition of more severe alcohol withdrawal. They should not be used alone, but only when combined with adequate sedative-hypnotic drug therapy. Beta-blockers that have been recommended include atenolol, metoprolol, propranolol, and labetalol. The usual contraindications for clonidine and beta-blockers apply.

Carbamazepine has been shown in some clinical trials to be effective in treating patients with minor symptoms of alcohol withdrawal and has been used extensively in Europe as monotherapy. There is insufficient evidence indicating that carbamazepine or other anticonvulsants are effective in the prevention or treatment of more severe manifestations of alcohol withdrawal, including DTs, but they appear to have limited side effects in this population.[24]

Drugs such as esmolol and midazolam, which have a short half-life and rapid onset of action, can be administered by continuous IV infusion and have been used in critically ill patients with DTs. Clinical studies have not shown them to be superior, or even equal, in overall effectiveness compared with longer-acting agents.

Neuroleptic drug therapy is inferior to sedative-hypnotic drug therapy in reducing mortality or the duration of severe alcohol withdrawal.[25] Neuroleptic drugs are associated with more adverse effects, including lowering of seizure threshold, hypotension, prolonged QT interval, and neuroleptic malignant syndrome. These precautions apply to the older neuroleptics. Little experience with the newer neuroleptics (atypical antipsychotics) exists in the treatment of alcohol withdrawal.

As the extreme hyperglutamatergic and hyperdopaminergic states that occur in severe alcohol withdrawal are thought to be responsible for paranoia, hallucinations, and agitated delirium, there may be a role for small titrated doses of dopamine antagonists (eg, haloperidol) in highly agitated patients, provided that adequate treatment with GABA coverage (benzodiazepines, phenobarbital) has been administered. Some authorities recommend haloperidol at a dose of 0.5-5 mg intravenously or intramuscularly every 30-60 minutes or the same dose orally every 4 hours for severe agitation, perceptual disturbances, or disturbed thinking not adequately controlled by high-dose benzodiazepines.



Class Summary

By acting on the GABA receptor, benzodiazepines produce a cross-tolerance to alcohol, thus reducing the hemodynamic and peripheral symptoms of alcohol withdrawal. The dose of benzodiazepine used should be based on the patient's symptoms and signs of alcohol withdrawal, including vital signs and amount of agitation. The longer-acting agents appear to be superior to the short-acting agents and may result in a smoother withdrawal course, with less breakthrough and rebound symptoms, although a risk of excessive sedation exists in certain patient groups (elderly patients, patients with liver failure) with the longer-acting agents.

For the treatment of minor or moderate alcohol withdrawal (in patients able to take oral therapy), symptom-triggered therapy (also known as prn therapy) has been shown in prospective, randomized, controlled trials to be superior to fixed-dose drug therapy, with less medication use and a shorter duration of therapy.[26] The dosage of benzodiazepine needs to be individualized for each patient. The successful use of symptom-triggered therapy requires motivated and attentive nursing.

Drug regimens and doses recommended for minor withdrawal are not appropriate for patients with delirium tremens (DTs), who often require very high doses of these agents. For the treatment of DTs, benzodiazepines should be administered only parenterally.

For patients with severe withdrawal symptoms, including DTs, the benzodiazepine dose should be front loaded. That is, large doses should be administered intravenously at short intervals until the patient is calm but easily aroused. Then additional doses are administered only as needed. Most authorities recommend intravenous diazepam as the first choice for front-loading treatment of severe alcohol withdrawal. Because of its long serum half-life, and the even longer half-life of its active metabolite (desmethyldiazepam), additional doses may not be required once the patient is calm.

Longer-acting benzodiazepines (especially those with active metabolites) provide less fluctuation in blood levels and allow a more gradual physiologic taper. A review of 4 randomized controlled trials of front-loaded diazepam concluded that it produces a rapid calming effect with few untoward adverse effects in medically ill patients, required much less total dose of benzodiazepines, and resulted in a shorter duration of treatment, but may result in over sedation and respiratory depression in very elderly persons or those with severe liver disease.[27] Aggressive treatment of severe alcohol withdrawal syndrome with diazepam may decrease the need for intubation.[9]

Intravenous lorazepam, which has an intermediate serum half-life and no active metabolites, has been successfully used and may be preferable in elderly persons or in those with severe liver disease. Reports describe a higher incidence of late-onset alcohol withdrawal seizures with use of shorter-acting benzodiazepines such as oxazepam or lorazepam.

No controlled studies show superiority of shorter-acting agents (propofol, pentobarbital, lorazepam, and midazolam) over diazepam or other long-acting benzodiazepines.

If the IV route is not available, then intramuscular lorazepam (or midazolam as an alternative) is recommended. Diazepam and chlordiazepoxide should not be administered intramuscularly, because absorption is erratic.

The use of continuous IV infusions of short-acting benzodiazepines (lorazepam, midazolam) has been reported, but these infusions have required very large amounts of drug and are very expensive. No evidence indicates that continuous infusion therapy with short-acting agents leads to better outcomes than does oral or intravenous intermittent bolus therapy with long-acting agents.

Patients with DTs who do not respond to high doses of benzodiazepines may respond to the addition of phenobarbital, propofol, or possibly dexmedetomidine to the treatment regimen.



Chlordiazepoxide depresses all levels of the central nervous system (CNS), including the limbic and reticular formations, possibly by increasing the activity of GABA, a major inhibitory neurotransmitter. The parenteral form is usually used initially. Because of limited experience with IV chlordiazepoxide for severe alcohol withdrawal and DTs, the use of IV diazepam or lorazepam is preferred.

Diazepam (Valium, Diastat)


Diazepam depresses all levels of CNS (eg, the limbic and reticular formations), possibly by increasing the activity of GABA. Individualize the dosage and increase cautiously to avoid adverse effects.

Because of its rapid onset, prolonged duration of effects, and high therapeutic index, diazepam is the drug of choice. Volumes of literature exist regarding the use of diazepam for ethanol withdrawal. The onset of action is within 5 minutes after IV administration. It has an active metabolite (desmethyldiazepam) that has a longer duration of action than that of diazepam.

Lorazepam (Ativan)


Lorazepam is a sedative hypnotic with a rapid onset of action and a medium duration of effect. By increasing the action of GABA, which is major inhibitory neurotransmitter in brain, it may depress all levels of the CNS, including the limbic and reticular formations. When the patient must be sedated for more than 24 hours, this medication is excellent, although it may require frequent redosing. Although diazepam is the preferred benzodiazepine, lorazepam is an excellent alternative and is especially useful in elderly persons and in those with severe hepatic dysfunction. It is commonly used prophylactically to prevent DTs. It can be given intramuscularly in patients lacking intravenous access.


Anesthetic agents

Class Summary

Propofol, an IV anesthetic agent, is active on the glutamate and GABA-A receptors, similar to alcohol itself, whereas benzodiazepines are active only against the GABA receptors. Due to its rapid onset of hypnosis and anticonvulsant properties, propofol is an alternative treatment for intubated patients with delirium tremens (DTs) who are refractory to high-dose benzodiazepines. Advantages to its use are that it is easily titratable, with predictable effects, and has a rapid metabolic clearance.

Propofol (Diprivan)


Propofol is a phenolic compound unrelated to other types of anticonvulsants. It has general anesthetic properties when administered intravenously. Propofol IV produces rapid hypnosis, usually within 40 seconds. The effects are reversed within 30 minutes, following the discontinuation of infusion. Propofol has also been shown to have anticonvulsant properties.



Class Summary

These agents have direct effects on the benzodiazepine ̶ GABA-A ̶ chloride receptor complex in enhancing chloride flux. Barbiturates may be useful in patients refractory to benzodiazepines. Respiratory depression is common at large doses. Ventilatory support may be required.



Phenobarbital has direct effects on the benzodiazepine-GABA-A-chloride receptor complex in enhancing chloride flux. It may be useful in patients refractory to benzodiazepines. The drug exhibits anticonvulsant properties in anesthetic doses. Because a barbiturate-induced respiratory depression may occur, especially after previous benzodiazepine therapy, early mechanical ventilation should be considered.

Pentobarbital (Nembutal)


Pentobarbital is a short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties and can produce all levels of CNS mood alteration.


Vitamins and Nutrients

Class Summary

These agents are used to treat the hypoglycemia and nutrient and electrolyte deficiencies associated with delirium tremens (DTs). Alcoholics usually are deficient in thiamine, which functions as a cofactor for a number of important enzymes, such as pyruvate dehydrogenase, transketolase, and alpha-ketoglutarate dehydrogenase. Deficiency leads to Wernicke encephalopathy, peripheral neuropathy, cardiomyopathy, and metabolic acidosis.

Alcoholics often are also magnesium deficient, due to poor nutritional status and malabsorption. Magnesium stabilizes membranes, helps in the maintenance of potassium and calcium homeostasis, and may protect against seizures and arrhythmias.

Patients suffering from alcoholism may also develop hypoglycemia, due to malnutrition and poor glycogen stores. Additionally, gluconeogenesis is impaired because of a relative reduced redox state resulting from alcohol metabolism, which uses NAD+ as a cofactor for alcohol dehydrogenase and aldehyde dehydrogenase. The relative excess of NADH shifts the pyruvate-to-lactate ratio toward lactate, decreasing the substrate for gluconeogenesis.

Dextrose (D-Glucose)


Dextrose is a monosaccharide absorbed from the intestine and distributed, stored, and used by tissues. Parenterally injected dextrose is used in patients who are unable to obtain adequate oral intake. Direct oral absorption results in a rapid increase of blood glucose concentrations. Dextrose is effective in small doses; there is no evidence of toxicity. Concentrated dextrose infusions provide higher amounts of glucose and increased caloric intake, with minimal fluid volume. Use 1 ampule of 50 mL of a 50% glucose solution (25 g).

Thiamine (Vitamin B-1)


This is used to treat thiamine deficiency, including Wernicke encephalopathy.

Folic acid (Folacin-800)


Dietary deficiency of folic acid is common in alcoholics. Folic acid is an important cofactor for enzymes used in the production of red blood cells.

Magnesium sulfate


Magnesium sulfate is used to treat and prevent seizures. It decreases the amount of acetylcholine liberated at the endplate by the motor nerve impulse. The drug blocks neuromuscular transmission associated with seizure activity. Magnesium also exercises CNS depressant effects by blocking the NMDA receptor. Monitor patients carefully; large doses of magnesium sulfate may cause respiratory depression, hyporeflexia, and bradycardia. Infusion should be discontinued if reflexes are absent or if magnesium levels exceed 6-8 mEq/L. Calcium chloride, 10 mL IV of a 10% solution, can be given as an antidote for clinically significant hypermagnesemia.

Contributor Information and Disclosures

Michael James Burns, MD, FACEP, FACP Health Science Clinical Professor, Department of Emergency Medicine, Department of Internal Medicine, Division of Infectious Diseases, University of California Irvine School of Medicine

Michael James Burns, MD, FACEP, FACP is a member of the following medical societies: Alpha Omega Alpha, American Geriatrics Society, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Phi Beta Kappa, Royal Society of Tropical Medicine and Hygiene, American College of Emergency Physicians, American College of Physicians, California Medical Association, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.


James B Price, MD Attending Emergency Physician, Mission Hospital; Clinical Faculty, Department of Emergency Medicine, Harbor-UCLA Medical Center

James B Price, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians

Disclosure: Nothing to disclose.

Michael E Lekawa, MD, FACS Associate Clinical Professor of Surgery, University of California, Irvine School of Medicine; Chief, Department of Surgery, Division of Trauma and Critical Care, Director of Trauma Services, Director of Surgical Intensive Care Unit, Director of Student Critical Care Teaching Program, Medical Director of Surgery Clinics, University of California, Irvine Medical Center

Michael E Lekawa, MD, FACS is a member of the following medical societies: American Association for the Surgery of Trauma, American College of Surgeons, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Chief Editor

Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM Professor of Critical Care Medicine, Bioengineering, Cardiovascular Disease, Clinical and Translational Science and Anesthesiology, Vice-Chair of Academic Affairs, Department of Critical Care Medicine, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine

Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM is a member of the following medical societies: American College of Chest Physicians, Association of University Anesthetists, European Society of Intensive Care Medicine, American College of Critical Care Medicine, American Heart Association, American Thoracic Society, Shock Society, Society of Critical Care Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Masimo<br/>Received honoraria from LiDCO Ltd for consulting; Received intellectual property rights from iNTELOMED for board membership; Received honoraria from Edwards Lifesciences for consulting; Received honoraria from Masimo, Inc for board membership.


Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

William K Chiang, MD Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

William K Chiang, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

William G Gossman, MD Associate Clinical Professor of Emergency Medicine, Creighton University School of Medicine; Consulting Staff, Department of Emergency Medicine, Creighton University Medical Center

William G Gossman, MD is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

J Stephen Huff, MD Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia School of Medicine

J Stephen Huff, MD is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Neurology, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Lisa Kirkland, MD, FACP, CNSP, MSHA Assistant Professor, Department of Internal Medicine, Division of Hospital Medicine, Mayo Clinic; ANW Intensivists, Abbott Northwestern Hospital

Lisa Kirkland, MD, FACP, CNSP, MSHA is a member of the following medical societies: American College of Physicians, Society of Critical Care Medicine, and Society of Hospital Medicine

Disclosure: Nothing to disclose.

Harold L Manning, MD Professor, Departments of Medicine, Anesthesiology and Physiology, Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School

Harold L Manning, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Sage W Wiener, MD Assistant Professor, Department of Emergency Medicine, State University of New York Downstate Medical Center; Assistant Director of Medical Toxicology, Department of Emergency Medicine, Kings County Hospital Center

Sage W Wiener, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Anne Yim, MD Resident Physician, Department of Emergency Medicine, Kings County Hospital and State University of New York Downstate Medical Center

Anne Yim, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

  1. Eyer F, Schuster T, Felgenhauer N, Pfab R, Strubel T, Saugel B. Risk assessment of moderate to severe alcohol withdrawal--predictors for seizures and delirium tremens in the course of withdrawal. Alcohol Alcohol. 2011 Jul-Aug. 46(4):427-33. [Medline].

  2. Kim DW, Kim HK, Bae EK, Park SH, Kim KK. Clinical predictors for delirium tremens in patients with alcohol withdrawal seizures. Am J Emerg Med. 2015 May. 33 (5):701-4. [Medline].

  3. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015 Aug. 72 (8):757-66. [Medline].

  4. Chan GM, Hoffman RS, Gold JA, Whiteman PJ, Goldfrank LR, Nelson LS. Racial variations in the incidence of severe alcohol withdrawal. J Med Toxicol. 2009 Mar. 5(1):8-14. [Medline].

  5. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989 Nov. 84(11):1353-7. [Medline].

  6. Watling SM, Fleming C, Casey P, Yanos J. Nursing-based protocol for treatment of alcohol withdrawal in the intensive care unit. Am J Crit Care. 1995 Jan. 4(1):66-70. [Medline].

  7. Reoux JP, Oreskovich MR. A comparison of two versions of the clinical institute withdrawal assessment for alcohol: the CIWA-Ar and CIWA-AD. Am J Addict. 2006 Jan-Feb. 15(1):85-93. [Medline].

  8. Khan BA, Guzman O, Campbell NL, Walroth T, Tricker J, Hui SL. Comparison and agreement between the Richmond Agitation-Sedation Scale and the Riker Sedation-Agitation Scale in evaluating patients' eligibility for delirium assessment in the ICU. Chest. 2012 Jul. 142(1):48-54. [Medline].

  9. Gold JA, Rimal B, Nolan A, Nelson LS. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med. 2007 Mar. 35(3):724-30. [Medline]. [Full Text].

  10. Duby JJ, Berry AJ, Ghayyem P, Wilson MD, Cocanour CS. Alcohol withdrawal syndrome in critically ill patients: protocolized versus nonprotocolized management. J Trauma Acute Care Surg. 2014 Dec. 77 (6):938-43. [Medline].

  11. Schmidt KJ, Doshi MR, Holzhausen JM, Natavio A, Cadiz M, Winegardner JE. A Review of the Treatment of Severe Alcohol Withdrawal. Ann Pharmacother. 2016 Feb 9. [Medline].

  12. Krishel S, SaFranek D, Clark RF. Intravenous vitamins for alcoholics in the emergency department: a review. J Emerg Med. 1998 May-Jun. 16(3):419-24. [Medline].

  13. Schabelman E, Kuo D. Glucose before thiamine for Wernicke encephalopathy: a literature review. J Emerg Med. 2012 Apr. 42 (4):488-94. [Medline].

  14. Sarai M, Tejani AM, Chan AH, Kuo IF, Li J. Magnesium for alcohol withdrawal. Cochrane Database Syst Rev. 2013 Jun 5. 6:CD008358. [Medline].

  15. Weinberg JA, Magnotti LJ, Fischer PE, et al. Comparison of intravenous ethanol versus diazepam for alcohol withdrawal prophylaxis in the trauma ICU: results of a randomized trial. J Trauma. 2008 Jan. 64(1):99-104. [Medline].

  16. Friedmann PD. Clinical practice. Alcohol use in adults. N Engl J Med. 2013 Jan 24. 368(4):365-73. [Medline].

  17. Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet. 2016 Mar 5. 387 (10022):988-98. [Medline].

  18. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011. (6):CD008537. [Medline].

  19. McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med. 2000 Jun. 28(6):1781-4. [Medline].

  20. Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. Am J Emerg Med. 2011 May. 29(4):382-5. [Medline].

  21. Rosenson J, Clements C, Simon B, Vieaux J, Graffman S, Vahidnia F. Phenobarbital for Acute Alcohol Withdrawal: A Prospective Randomized Double-blind Placebo-controlled Study. J Emerg Med. 2013 Mar. 44(3):592-598.e2. [Medline].

  22. Foster C, Mueller S, Vanderweide L, Kiser T, Fish D, MacLaren R. Addition of dexmedetomidine to the standard of care for severe alcohol withdrawal [abstr]. Critic Care Med. 2012 Dec. 40(12):doi: 10.1097/01.ccm.0000424341.32883.e7.

  23. Linn DD, Loeser KC. Dexmedetomidine for Alcohol Withdrawal Syndrome. Ann Pharmacother. 2015 Dec. 49 (12):1336-42. [Medline].

  24. Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2010. (3):CD005064. [Medline].

  25. Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004 Jul 12. 164(13):1405-12. [Medline].

  26. Jaeger TM, Lohr RH, Pankratz VS. Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients. Mayo Clin Proc. 2001 Jul. 76(7):695-701. [Medline].

  27. Muzyk AJ, Leung JG, Nelson S, Embury ER, Jones SR. The role of diazepam loading for the treatment of alcohol withdrawal syndrome in hospitalized patients. Am J Addict. 2013 Mar. 22(2):113-8. [Medline].

Average annual deaths from alcohol.
Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar). The CIWA-Ar is not copyrighted and may be reproduced freely. This assessment for monitoring withdrawal symptoms requires approximately 5 minutes to administer. The maximum score is 67 (see instrument). Patients scoring less than 10 do not usually need additional medication for withdrawal. From Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction 1989;84:1353-1357.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.